Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
The Journal of Antimicrobial Chemotherapy|July 12, 2007
Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05Gregory Steinkraus, Roger White, Lawrence FriedrichDiagnostic Microbiology and Infectious Disease|September 19, 2009
Evidence for daptomycin Etest lot-related MIC elevations for Staphylococcus aureusLawrence Friedrich, Grace Thorne, Judith N Steenbergen, et al.Current Medical Research and Opinion|August 3, 2007
Effectiveness and duration of daptomycin therapy in resolving clinical symptoms in the treatment of complicated skin and skin structure infectionsJake E Krige, Kimberly Lindfield, Lawrence Friedrich, et al.Antimicrobial Agents and Chemotherapy|April 15, 2020
Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection ModelBrian D VanScoy, Elizabeth A Lakota, Haley Conde, et al.Antimicrobial Agents and Chemotherapy|July 31, 2024
Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infectionsSujata M Bhavnani, Jeffrey P Hammel, Elizabeth A Lakota, et al.Antimicrobial Agents and Chemotherapy|April 29, 2020
Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 DataElizabeth A Lakota, Scott A Van Wart, Michael Trang, et al.Antimicrobial Agents and Chemotherapy|March 22, 2023
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzaeSujata M Bhavnani, Jeffrey P Hammel, Elizabeth A Lakota, et al.Pageof 1